Dislipidemia como factor de riesgo para el desarrollo de retinopatía diabética en pacientes de la consulta externa del hospital Luis Vernaza

Andrés Fernando Pólit Hoyos

Resumen


Introducción: la asociación entre retinopatía diabética y los niveles de lípidos sigue sin aclararse. En este estudio, se intenta investigar la asociación entre la retinopatía diabética y los niveles elevados de lípidos en pacientes con diabetes tipo 2. Métodos: se seleccionaron los pacientes que acudieron a su primera consulta oftalmológica en el hospital Luis Vernaza desde agosto de 2013 a enero de 2014. Para el análisis fueron divididos en dos grupos, uno con menos de 10 años de diagnóstico con diabetes mellitus 2 y el otro con 10 o más años. Resultados: 67 ojos fueron incluidos, de los cuales 7 (10 %) presentaron retinopatía diabética proliferativa y 24 retinopatía diabética no proliferativa. 69% de los casos presentaron dislipidemia, 37 casos tuvieron menos de 10 años con diabetes mellitus 2 y 30 tuvieron 10 años o más. El grupo con dislipidemia presentó significativamente más RDNP y RDP que el grupo sin dislipidemia (p=0,0074). Conclusión: los pacientes con  dislipidemia se asociaron con porcentajes mayores de la retinopatía diabética. Por este motivo recomendamos  que el control lipídico pudiera ayudar a disminuir el riesgo de retinopatía diabética.

Palabras clave


Retinopatía Diabética; Dislipidemia; Glucemia.

Texto completo:

PDF

Referencias


Simó R, Hernández C. Prevention and Treatment of Diabetic Retinopathy: Evidence from Large, Randomized Trials. The Emerging Role of Fenofibrate. Reviews on Recent Clinical Trials, 2012, 7, 71-80 .

Aldebasi YH, Mohieldein AH, Almansour YS, Almutairi BL. Dyslipidemia and lipid peroxidation of Saudi type 2 diabetics with proliferative retinopathy. Saudi Med J 2013; Vol 34.

Asensio-Sánchez VM, Gómez-Ramírez V, Morales-Gómez I, Rodríguez-Vaca I. Edema macular diabético clínicamente significativo: factores sistémicos de riesgo. ARCH SOC ESP OFTALMOL 2008; 83: 173-176.

Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol. 2012;57(4):347–370.

Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of Diabetic Retinopathy in the United States, 2005-2008. JAMA 2010; 304: 649-656.

Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008;115:1869–1875.

Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.

Wang FH, Liang YB, Zhang F, Wang JJ, Wei WB, Tao QS, et al. Prevalence of diabetic retinopathy in rural China: The Handan Eye Study. Ophthalmology 2009;116:461-7.

Cetin E, Bulgu Y, Ozdemir S, Topsakal S, Akin F, Aybek H, Yildirim C. Association of serum lipid levels with diabetic retinopathy. Int J Ophthalmol. 2013; 6(3): 346–349.

The ACCORD Study Group and ACCORD Eye Study Group; Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44.

Alvarez R. Retinopatía diabética. Boletin de la escuela de medicina. 2006. Vol 31 N°2.

Ozer PA, Unlu N, Demir MN, Hazirolan DO, Acar MA, Duman S. Serum lipid profile in diabetic macular edema. J Diabetes Complications. 2009;23(4):244–248.

Gadi R, Samaha FF. Dyslipidemia in Type 2 Diabetes Mellitus. Current Diabetes Reports 2007; 7: 228-234.

Muhammad Bayu Sasongko, MD, MEPI, Tien Y. Wong, MPH, PHD, Thanh T. Nguyen, MBBS, PHD, Ryo Kawasaki, MPH, PHD, Alicia Jenkins, MBBS, MD, Jonathan Shaw, MD, and Jie Jin Wang, MMED, PHD. Serum Apolipoprotein AI and B Are Stronger Biomarkers of Diabetic Retinopathy Than Traditional Lipids. Diabetes Care. 2011 February; 34(2): 474–479.

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36.

Idiculla J, Nithyanandam S, Joseph M, Mohan VA, Vasu U, Sadiq M. Serum lipids and diabetic retinopathy: A cross-sectional study. Indian J Endocrinol Metab. 2012;16(Suppl 2):S492–494.

Simo R, Garcia-Ramirez M, Higuera M, Hernandez C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol 2009;147:319–325 e311.

Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X, et al. Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2012; 250: 957-962.

Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins A, Shaw J, et al. Serum Apolipoprotein AI and B Are Stronger Biomarkers of Diabetic Retinopathy than Traditional Lipids. Diabetes Care 2011; 34: 474-479.

Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study.Ophthalmology. 2008;115(11):1869–1875.

Benarous R, Sasongko MB, Qureshi S, Fenwick E, Dirani M, Wong TY, Lamoureux EL. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema.Invest Ophthalmol Vis Sci. 2011;52(10):7464–7469.

Sachdev N, Sahni A. Association of systemic risk factors with the severity of retinal hard exudates in a north Indian population with type 2 diabetes. J Postgrad Med. 2010;56(1):3–6.

Raman R, Rani PK, Kulothungan V, Rachepalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010;117(4):766–772.

Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The wisconsin epidemiologic study of diabetic retinopathy XXIII: The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503.

Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: A systematic review and meta-analysis. Diabetes Care 2009;32:2307-13.

Davis TM, Ting R, Best JD, Donoghoe MW, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-90.

David A. Antonetti, Ph.D., Ronald Klein, M.D., M.P.H., and Thomas W. Gardner, M.D. Diabetic Rethinopathy. N Engl J Med 2012;366:1227-39.






Revista Medicina - Universidad Católica de Santiago de Guayaquil - Facultad de Ciencias Médicas